Drugs Made In America Acquisition Corp. Ordinary Shares

Drugs Made In America Acquisition Corp. Ordinary Shares

DMAA·NASDAQ

$10.61

+0.094%
Financial ServicesShell Companies

Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.

At a Glance

Live Snapshot
Market Cap$357.74M
EPS0.1900
P/E Ratio55.84
Earnings Date

dmaa

Operating Cash Flow

Last Annual Value

-539.19K

3-Year CAGR

-1123%

5-Year CAGR

-349%

10-Year CAGR

-112%

Drugs Made In America Acquisition Corp. Ordinary Shares

Drugs Made In America Acquisition Corp. Ordinary Shares Competitors Analysis of Operating Cash Flow

DMAA · NASDAQ
CompanyOperating Cash Flow
CAGR 3Y
CAGR 5Y
CAGR 10Y
-539.19K
N/AN/AN/A 
-631.66K
N/AN/AN/A
-564.45K
N/AN/AN/A
-576.61K
N/AN/AN/A
-567.93K
N/AN/AN/A
-1.28M
N/AN/AN/A
-991.95K
N/AN/AN/A
-1.26M
N/AN/AN/A
-1.26M
N/AN/AN/A
Drugs Made In America Acquisition Corp. Ordinary Shares

Drugs Made In America Acquisition Corp. Ordinary Shares Fair Value Envelope

DMAA · NASDAQ

Our analysis suggests that DMAA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $10.61, this represents a potential HIDDEN relative to our calculated worth for Drugs Made In America Acquisition Corp. Ordinary Shares.

Intrinsic Value
Current Price: $10.61